Annex 12A

CHAPTER 10.4.  
  
**INFECTION WITH HIGH PATHOGENICITY AVIAN INFLUENZA VIRUSES**

Article 10.4.1.

**General provisions**

1) This chapter deals with the *listed disease*, *infection* with high pathogenicity avian influenza viruses.

2) For the purposes of the *Terrestrial Code*:

*a)* High pathogenicity avian influenza means an *infection* of *poultry* by any influenza A virus that has been determined as high pathogenicity in accordance with the *Terrestrial Manual*.

*b)* An occurrence of *infection* with a high pathogenicity avian influenza virus is defined by the isolation and identification of the virus or the detection of specific viral ribonucleic acid, in one or more samples from *poultry*.

*c)* The *incubation period* at the *flock-*level for high pathogenicity avian influenza is 14 days.

3) Although the objective of this chapter is to mitigate animal and public health risks posed by *infection* with high pathogenicity avian influenza viruses, other influenza A viruses of avian host origin (i.e. low pathogenicity avian influenza viruses) may have the potential to exert a negative impact on animal and public health. A sudden and unexpected increase in virulence of low pathogenicity avian influenza viruses in *poultry* is notifiable as an *emerging disease* in accordance with Article 1.1.4. *Infection* of domestic and *captive wild* birds with low pathogenicity avian influenza viruses having proven natural transmission to humans associated with severe consequences, and *infection* of birds other than *poultry,* including *wild* birds, with influenza A viruses of high pathogenicity, are notifiable in accordance with Article 1.3.6.

4) A *notification* of *infection* of birds other than *poultry,* including *wild* birds, with influenza A viruses of high pathogenicity, or of *infection* of *poultry* or *captive wild* birds with low pathogenicity avian influenza viruses does not affect the high pathogenicity avian influenza status of the country or *zone*. A Member Country should not impose bans on the trade of *poultry* *commodities* in response to such *notifications*, or to other information on the presence of any influenza A virus in birds.

5) This chapter includes *monitoring* considerations for low pathogenicity avian influenza viruses because some, especially H5 and H7 subtypes, have the potential to mutate into high pathogenicity avian influenza viruses.

6) The use of *vaccination* against avian influenza may be recommended under specific conditions. Any vaccine used should comply with the standards described in the *Terrestrial Manual*. *Vaccination* will not affect the high pathogenicity avian influenza status of a free country or *zone* if *surveillance* supports the absence of *infection*, in accordance with Article 10.4.22., in particular point 2. *Vaccination* can be used as an effective complementary control tool when a *stamping-out policy* alone is not sufficient. Whether to vaccinate or not should be decided by the *Veterinary Authority* on the basis of the avian influenza situation as well as the ability of the *Veterinary Services* to implement the *vaccination* strategy, as described in Chapter 4.18.

7) Standards for diagnostic tests and vaccines, including pathogenicity testing, are described in the *Terrestrial Manual*.

Annex 12A (contd)

Article 10.4.1bis.

**Safe commodities**

When authorising importation or transit of the following *commodities*, *Veterinary Authorities* should not require any conditions related to high pathogenicity avian influenza, regardless of the high pathogenicity avian influenza status of the *exporting country* or *zone*:

1) heat-treated *poultry* *meat* *products* in a hermetically sealed container with an F0 value of 3 or above;

2) extruded dry pet food and coated ingredients after extrusion;

3) rendered *meat* and bone meal, blood meal, feather meal, and *poultry* oil;

4) washed and steam-dried feathers and down from *poultry* and other birds.

Other *commodities* of *poultry* and other birds can be traded safely if in accordance with the relevant articles of this chapter.

Article 10.4.2.

**Country or zone free from high pathogenicity avian influenza**

A country or *zone* may be considered free from high pathogenicity avian influenza when:

‒ *infection* with high pathogenicity avian influenza viruses is a *notifiable disease* in the entire country;

‒ an ongoing awareness programme is in place to encourage reporting of suspicions of high pathogenicity avian influenza;

‒ absence of *infection* with high pathogenicity avian influenza viruses, based on *surveillance*, in accordance with Chapter 1.4. and Articles 10.4.20. to 10.4.22ter., has been demonstrated in the country or *zone* for the past 12 months;

‒ an awareness programme is in place related to *biosecurity* and management of avian influenza viruses;

‒ *commodities* are imported in accordance with Articles 10.4.3. to 10.4.17bis.

*Surveillance* should be adapted to parts of the country or existing *zones* depending on historical or geographical factors, industry structure, population data and proximity to recent *outbreaks* or the use of *vaccination*.

Article 10.4.2bis.

**Compartment free from high pathogenicity avian influenza**

The establishment of a *compartment* free from high pathogenicity avian influenza should be in accordance with relevant requirements of this chapter and the principles described in Chapters 4.4. and 4.5.

Article 10.4.2ter.

**Establishment of a containment zone within a country or zone free from high pathogenicity avian influenza**

In the event of *outbreaks* of high pathogenicity avian influenza within a previously free country or *zone*, a *containment* *zone*, which includes all epidemiologically linked *outbreaks*, may be established for the purpose of minimising the impact on the rest of the country or *zone*.

Annex 12A (contd)

In addition to the requirements for the establishment of a *containment zone* outlined in Article 4.4.7., the *surveillance* programme should take into account the density of *poultry* production, types of *poultry*, local management practices (including inter-premises movement patterns of *poultry*, people and equipment), relevant *biosecurity*, the presence and potential role of birds other than *poultry*, including *wild* birds, and the proximity of *poultry* *establishment*s to permanent and seasonal water bodies.

The free status of the areas outside the *containment zone* is suspended while the *containment zone* is being established. It may be reinstated, irrespective of the provisions of Article 10.4.2quater., once the *containment zone* is clearly established. It should be demonstrated that *commodities* for *international trade* have originated from outside the *containment zone* or comply with the relevant articles of this chapter.

Article 10.4.2quater.

**Recovery of free status**

If *infection* with high pathogenicity avian influenza virus has occurred in *poultry* in a previously free country or *zone*, the free status may be regained after a minimum period of 28 days (i.e. two *flock*-level *incubation periods*) after a *stamping-out policy* has been completed (i.e. after the *disinfection* of the last affected *establishment*), provided that *surveillance* in accordance with Articles 10.4.20. to 10.4.22ter., in particular point 3 of Article 10.4.22., has been carried out during that period and has demonstrated the absence of *infection*.

If a *stamping-out policy* is not implemented, Article 10.4.2. applies.

Article 10.4.3.

**Recommendations for importation from a country, zone or compartment free from high pathogenicity avian influenza**

For live poultry (other than day-old poultry)

*Veterinary Authorities* should require the presentation of an *international veterinary certificate* attesting that:

1) the *poultry* showed no clinical signs of avian influenza on the day of shipment;

2) the *poultry* originated from a country, *zone* or *compartment* free from high pathogenicity avian influenza;

3) the *poultry* originated from a *flock* that was monitored for avian influenza viruses and was found to be negative;

4) the *poultry* are transported in new or appropriately sanitised *containers*.

If the *poultry* have been vaccinated against avian influenza viruses, the nature of the vaccine used and the date of *vaccination* should be stated in the *international veterinary certificate*.

Article 10.4.4.

**Recommendations for the importation of live birds other than poultry**

Regardless of the high pathogenicity avian influenza status of the country of origin, *Veterinary Authorities* should require the presentation of an *international veterinary certificate* attesting that:

1) on the day of shipment, the birds showed no clinical signs of avian influenza;

2) the birds had been kept in isolation facilities approved by the *Veterinary Services* since they were hatched or for at least 28 days (i.e. two *flock*-level *incubation periods*) prior to shipment and showed no clinical signs of avian influenza during the isolation period;

Annex 12A (contd)

3) a statistically appropriate sample of the birds was subjected, with negative results, to a diagnostic test for avian influenza within 14 days prior to shipment;

4) the birds are transported in new or appropriately sanitised *containers*.

If the birds have been vaccinated against avian influenza, the nature of the vaccine used and the date of *vaccination* should be stated in the *international veterinary certificate*.

Article 10.4.5.

**Recommendations for importation from a country, zone or compartment free from high pathogenicity avian influenza**

For day-old live poultry

*Veterinary Authorities* should require the presentation of an *international veterinary certificate* attesting that:

1) the day-old live *poultry* had been kept in a country, *zone* or *compartment* free from high pathogenicity avian influenza since they were hatched;

and

*a)* the day-old live *poultry* were derived from parent *flocks* that were monitored for avian influenza viruses and were found to be negativeat the time of collection of the eggs from which the day-old *poultry* hatched; or

*b)* the day-old live *poultry* that hatched from eggs that had had their surfaces sanitised in accordance with point 4 d)of Article 6.5.5.;

AND

2) the day-old live *poultry* were transported in new or appropriately sanitised *containers*.

If the day-old live *poultry* or the parent *flocks* have been vaccinated against avian influenza, the nature of the vaccine used and the date of *vaccination* should be stated in the *international veterinary certificate*.

Article 10.4.6.

**Recommendations for the importation of day-old live birds other than poultry**

Regardless of the high pathogenicity avian influenza status of the country of origin, *Veterinary Authorities* should require the presentation of an *international veterinary certificate* attesting that:

1) on the day of shipment, the birds showed no clinical signs of avian influenza;

2) the birds were hatched and kept in isolation facilities approved by the *Veterinary Services*;

3) a statistically appropriate sample of the parent *flock* birds were subjected, with negative results, to a diagnostic test for avian influenza at the time of collection of the eggs;

4) the birds were transported in new or appropriately sanitised *containers*.

If the birds or parent *flocks* have been vaccinated against avian influenza, the nature of the vaccine used and the date of *vaccination* should be stated in the *international veterinary certificate*.

Annex 12A (contd)

Article 10.4.7.

**Recommendations for importation from a country, zone or compartment free from high pathogenicity avian influenza**

For hatching eggs of poultry

*Veterinary Authorities* should require the presentation of an *international veterinary certificate* attesting that:

1) the hatching eggs came from a country, *zone* or *compartment* free from high pathogenicity avian influenza;

2) *a)* the hatching eggs were derived from parent *flocks* that were monitored for avian influenza viruses and were found to be negative at the time of collection of the hatching eggs; or

*b*) the hatching eggs have had their surfaces sanitised in accordance with point 4 d) of Article 6.5.5.;

3) the hatching eggs are transported in new or appropriately sanitised packaging materials and *containers*.

If the parent *flocks* have been vaccinated against avian influenza, the nature of the vaccine used and the date of *vaccination* should be stated in the *international veterinary certificate*.

Article 10.4.8.

**Recommendations for the importation of hatching eggs from birds other than poultry**

Regardless of the high pathogenicity avian influenza status of the country of origin, *Veterinary Authorities* should require the presentation of an *international veterinary certificate* attesting that:

1) a statistically appropriate sample of the parent *flock* birds was subjected, with negative results, to a diagnostic test for avian influenza 14 days prior to and at the time of collection of the hatching eggs;

2) the hatching eggs have had their surfaces sanitised in accordance with point 4 d)of Article 6.5.5.;

3) the hatching eggs are transported in new or appropriately sanitised packaging materials and *containers*.

If the parent *flocks* have been vaccinated against avian influenza, the nature of the vaccine used and the date of *vaccination* should be stated in the *international veterinary certificate*.

Article 10.4.9.

**Recommendations for importation from a country, zone or compartment free from high pathogenicity avian influenza**

For poultry semen

*Veterinary Authorities* should require the presentation of an *international veterinary certificate* attesting that the donor *poultry*:

1) showed no clinical signs of avian influenza on the day of semen collection;

2) were kept in a country, *zone* or *compartment* free from high pathogenicity avian influenza.

Article 10.4.10.

**Recommendations for the importation of semen from birds other than poultry**

Regardless of the high pathogenicity avian influenza status of the country of origin, *Veterinary Authorities* should require the presentation of an *international veterinary certificate* attesting that the donor birds:

1) were kept in isolation facilities approved by the *Veterinary Services* for at least 28 days (i.e. two *flock*-level *incubation periods*) prior to semen collection;

2) showed no clinical signs of avian influenza during the isolation period;

3) were subjected, with negative results, to a diagnostic test for avian influenza within 14 days prior to semen collection.

Annex 12A (contd)

Article 10.4.11.

**Recommendations for importation from a country, zone or compartment free from high pathogenicity avian influenza**

For eggs for human consumption

*Veterinary Authorities* should require the presentation of an *international veterinary certificate* attesting that:

1) the eggs for human consumption were produced and packed in a country, *zone* or *compartment* free from high pathogenicity avian influenza;

2) the eggs for human consumption were transported in new or appropriately sanitised packaging materials and *containers*.

Article 10.4.12.

**Recommendations for the importation of egg products from poultry**

Regardless of the high pathogenicity avian influenza status of the country of origin, *Veterinary Authorities* should require the presentation of an *international veterinary certificate* attesting that:

1) the egg products are derived from eggs which meet the requirements of Article 10.4.11.; or

2) theegg products have been processed to ensure the inactivation of high pathogenicity avian influenza viruses, in accordance with Article 10.4.18.;

AND

3) the necessary precautions were taken to avoid contact of theegg products with any source of high pathogenicity avian influenza viruses.

Article 10.4.13.

**Recommendations for importation from a country, zone or compartment free from high pathogenicity avian influenza**

For fresh meat of poultry

*Veterinary Authorities* should require the presentation of an *international veterinary certificate* attesting that the entire consignment of *fresh meat* comes from *poultry*:

1) which originated from a country, *zone* or *compartment* free from high pathogenicity avian influenza;

2) which were slaughtered in an approved *slaughterhouse/abattoir* in a country, *zone* or *compartment* free from high pathogenicity avian influenza and were subjected to ante- and post-mortem inspections in accordance with Chapter 6.3., with favourable results.

Article 10.4.14.

**Recommendations for the importation of meat products from poultry**

Regardless of the high pathogenicity avian influenza status of the country of origin, *Veterinary Authorities* should require the presentation of an *international veterinary certificate* attesting that:

1) the *meat products* from *poultry* are derived from *fresh meat* which meets the requirements of Article 10.4.13.; or

2) the *meat products* from *poultry* have been processed to ensure the inactivation of high pathogenicity avian influenza viruses in accordance with Article 10.4.19.;

AND

3) the necessary precautions were taken to avoid contact of the *meat products* from *poultry* with any source of high pathogenicity avian influenza viruses.

Annex 12A (contd)

Article 10.4.15.

**Recommendations for the importation of poultry products not listed in Article 10.4.1bis. and intended for use in animal feeding, or for agricultural or industrial use**

Regardless of the high pathogenicity avian influenza status of the country of origin, *Veterinary Authorities* should require the presentation of an *international* *veterinary certificate* attesting that:

1) these *commodities* were obtained from *poultry* which originated in a country, *zone* or *compartment* free from high pathogenicity avian influenza and that the necessary precautions were taken to avoid contamination during processing with any source of high pathogenicity avian influenza viruses;

OR

2) these *commodities* have been processed to ensure the inactivation of high pathogenicity avian influenza viruses using:

*a)* moist heat treatment for 30 minutes at 56°C; or

*b)* heat treatment where the internal temperature throughout the product reached at least 74°C; or

*c)* any equivalent treatment that has been demonstrated to inactivate avian influenza viruses;

AND

3) the necessary precautions were taken to avoid contact of the *commodity* with any source of high pathogenicity avian influenza viruses.

Article 10.4.16.

**Recommendations for the importation of feathers and down from poultry not listed in Article 10.4.1bis.**

*Veterinary Authorities* should require the presentation of an *international veterinary certificate* attesting that:

1) these *commodities* originated from *poultry* as described in Article 10.4.13. and were processed in a country, *zone* or *compartment* free from high pathogenicity avian influenza; or

2) these *commodities* have been processed to ensure the inactivation of high pathogenicity avian influenza viruses using one of the following:

*a)* fumigation with formalin (10% formaldehyde) for 8 hours;

*b)* irradiation with a dose of 20 kGy;

*c)* any equivalent treatment which has been demonstrated to inactivate avian influenza viruses;

AND

3) the necessary precautions were taken to avoid contact of the *commodity* with any source of high pathogenicity avian influenza viruses.

Article 10.4.17.

**Recommendations for the importation of feathers and down of birds other than poultry not listed in Article 10.4.1bis.**

Regardless of the high pathogenicity avian influenza status of the country of origin, *Veterinary Authorities* should require the presentation of an *international veterinary certificate* attesting that:

Annex 12A (contd)

1) these *commodities* have been processed to ensure the inactivation of high pathogenicity avian influenza viruses using one of the following:

*a)* fumigation with formalin (10% formaldehyde) for 8 hours;

*b)* irradiation with a dose of 20 kGy;

*c)* any equivalent treatment which has been demonstrated to inactivate avian influenza viruses;

2) the necessary precautions were taken to avoid contact of the *commodity* with any source of high pathogenicity avian influenza viruses.

Article 10.4.17bis.

**Recommendations for the importation of collection specimens, skins and trophies of birds other than poultry**

Regardless of the high pathogenicity avian influenza status of the country of origin, *Veterinary Authorities* should require the presentation of an *international* *veterinary certificate* attesting that:

1) these *commodities* have been processed to ensure the inactivation of high pathogenicity avian influenza viruses in accordance with Article 10.4.19bis.;

AND

2) the necessary precautions were taken to avoid contact of the *commodity* with any source of high pathogenicity avian influenza viruses.

Article 10.4.18.

**Procedures for the inactivation of high pathogenicity avian influenza viruses in egg products from poultry**

The following time/temperature combinations are suitable for the inactivation of high pathogenicity avian influenza viruses present in egg products:

|  | **Core temperature (°C)** | **Time** |
| --- | --- | --- |
| Whole egg | 60 | 188 seconds |
| Whole egg blends | 60 | 188 seconds |
| Whole egg blends | 61.1 | 94 seconds |
| Liquid egg white | 55.6 | 870 seconds |
| Liquid egg white | 56.7 | 232 seconds |
| Plain or pure egg yolk | 60 | 288 seconds |
| 10% salted yolk | 62.2 | 138 seconds |
| Dried egg white | 67 | 20 hours |
| Dried egg white | 54.4 | 50.4 hours |
| Dried egg white | 51.7 | 73.2 hours |

These time/temperature combinations are indicative of a range that achieves a 7-log10 reduction of avian influenza virus infectivity. These are examples for a variety of egg products but, when supported by scientific evidence, variations of these time/temperature combinations may be used, and they may be used for other egg products, if they achieve equivalent inactivation of the virus.

Annex 12A (contd)

Article 10.4.19.

**Procedures for the inactivation of high pathogenicity avian influenza viruses in meat products from poultry**

The following time/temperature combinations are suitable for the inactivation of high pathogenicity avian influenza viruses in *meat products*.

|  | **Core temperature (°C)** | **Time** |
| --- | --- | --- |
| Meat products from poultry | 60.0 | 507 seconds |
| 65.0 | 42 seconds |
| 70.0 | 3.5 seconds |
| 73.9 | 0.51 second |

These time/temperature combinations are indicative of a range that achieves a 7-log10 reduction of avian influenza virus infectivity. When supported by scientific evidence, variations of these time/temperature combinations may be used if they achieve equivalent inactivation of the virus.

Article 10.4.19bis.

**Procedures for the inactivation of high pathogenicity avian influenza viruses in collection specimens and in skins and trophies**

For the inactivation of high pathogenicity avian influenza viruses in collection specimens and in skins and trophies, one of the following procedures should be used:

1) boiling in water for an appropriate time to ensure that any material other than bone, claws or beaks is removed; or

2) soaking, with agitation, in a 4% (w/v) solution of washing soda (sodium carbonate-Na2CO3) maintained at pH 11.5 or above for at least 48 hours; or

3) soaking, with agitation, in a formic acid solution (100 kg salt [NaCl] and 12 kg formic acid per 1,000 litres water) maintained below pH 3.0 for at least 48 hours; wetting and dressing agents may be added; or

4) in the case of raw hides, treatment for at least 28 days with salt (NaCl) containing 2% washing soda (sodium carbonate-Na2CO3); or

5) treatment with 1% formalin for a minimum of six days; or

6) any equivalent treatment which has been demonstrated to inactivate the virus.

Article 10.4.20.

**Principles of surveillance for avian influenza**

The following are complementary to Chapter 1.4. and should be applied by Member Countries seeking to determine their high pathogenicity avian influenza status.

These principles are also necessary to support *vaccination* programmes, to monitor low pathogenicity avian influenza viruses, especially H5 and H7, in *poultry* and to detect high pathogenicity avian influenza in *wild* birds.

Annex 12A (contd)

The impact and epidemiology of avian influenza differ widely among different regions of the world and therefore it is impossible to provide detailed recommendations for all situations. Variables such as the frequency of contacts between *poultry* and *wild* birds, different *biosecurity* levels and production systems, and the commingling of different susceptible species including domestic waterfowl, may require different *surveillance* strategies to address each situation. Furthermore, domestic waterfowl typically do not show clinical signs and have longer infective periods than gallinaceous *poultry*. It is therefore incumbent upon the Member Country to provide scientific data that explain the epidemiology of avian influenza in the region of concern and also to demonstrate how all the risk factors have been taken into account. Member Countries have flexibility to provide a science-based approach to demonstrate absence of *infection* with high pathogenicity avian influenza viruses at an appropriate level of confidence, as described in Chapter 1.4.

There is an increased recognition of the value of the application of sequencing technologies and phylogenetic analyses to determine routes of introduction, transmission pathways and epidemiological patterns of *infection*. When avian influenza viruses are detected, Member Countries should apply these technologies, when possible, to enhance the evidence used to develop specific *surveillance* strategies and control activities.

A *monitoring* system for low pathogenicity avian influenza viruses in *poultry* should be in place for the following reasons:

1) Some H5 and H7 low pathogenicity avian influenza viruses have the potential to mutate into high pathogenicity avian influenza viruses and currently it is not possible to predict whether and when this mutation will occur.

2) The detection of sudden and unexpected increases in virulence of low pathogenicity avian influenza viruses in *poultry*, in order to fulfil notification obligations of an *emerging disease* in accordance with Article 1.1.4.

3) The detection, in domestic and *captive wild* birds, of low pathogenicity avian influenza viruses that have been proven to be transmitted naturally to humans with severe consequences is notifiable in accordance with Article 1.1.3.

Article 10.4.21.

**Surveillance for early warning of high pathogenicity avian influenza**

1) An ongoing *surveillance* programmefor avian influenza should be in place and be designed to detect the presence of *infection* with high pathogenicity avian influenza viruses in the country or *zone* in a timely manner.

2) The high pathogenicity avian influenza *surveillance* programme should include the following.

*a)* An *early warning system* for reporting suspected *cases*, in accordance with Article 1.4.5. throughout the production, marketing and processing chain. Farmers and workers who have day-to-day contact with *poultry*, as well as diagnosticians, should report promptly any suspicion of avian influenza to the *Veterinary Authority*. All suspected *cases* of high pathogenicity avian influenza should be investigated immediately and samples should be taken and submitted to a *laboratory* for appropriate tests.

*b)* Implementation, as relevant, of regular and frequent clinical inspection, or serological and virological testing, of high-risk groups of *animals*, such as those adjacent to a country or *zone* infected with high pathogenicity avian influenza, places where birds and *poultry* of different origins are mixed, such as live bird markets, and *poultry* in close proximity to waterfowl or other potential sources of influenza A viruses. This activity is particularly applicable to domestic waterfowl, where detection of high pathogenicity avian influenza via clinical suspicion can be of low sensitivity.

*c)* Immediate investigation of the presence of antibodies against influenza A viruses that have been detected in *poultry* and are not a consequence of *vaccination*. In the case of single or isolated serological positive results, *infection* with high pathogenicity avian influenza viruses may be ruled out on the basis of a thorough epidemiological and *laboratory* investigation that does not demonstrate further evidence of such an *infection*.

Annex 12A (contd)

Article 10.4.22.

**Surveillance for demonstrating freedom from infection with high pathogenicity avian influenza**

1. A Member Country declaring freedom of the entire country, a *zone* or a *compartment* from high pathogenicity avian influenza in *poultry* should provide evidence of an effective *surveillance* programme.

Transparency in the application of different methodologies is essential to ensure consistency in decision-making, ease of understanding, fairness and rationality. The assumptions made, the uncertainties, and the effect of these on the interpretation of the results, should be documented.

The design of the *surveillance* programme will depend on the epidemiological circumstances and it should be planned and implemented in accordance with this chapter and Article 1.4.6. This requires the availability of demographic data on the *poultry* population and the support of a *laboratory* able to undertake identification of *infection* with avian influenza viruses through virus detection and antibody tests.

The *surveillance* programme should demonstrate absence of *infection* with high pathogenicity avian influenza viruses during the preceding 12 months in susceptible *poultry* populations (vaccinated and non-vaccinated).

The design of the sampling strategy should include an epidemiologically appropriate design prevalence. The design prevalence and desired level of confidence in the results will determine the sample size. The Member Country should justify the choice of design prevalence and confidence level used on the basis of the stated objectives of the *surveillance* and the epidemiological situation.

The sampling strategy may be risk-based if scientific evidence is available, and provided, for the quantification of risk factors. Specific risks could include those linked to the types of production, possible direct or indirect contact with *wild* birds, multi-age *flocks*, local trade patterns including live bird markets, use of possibly contaminated surface water, the presence of more than one species at the *establishment* and poor *biosecurity* in place.

Data from different *surveillance* activities can be included to increase the sensitivity of the *surveillance* system. If this is to be done, data from structured (e.g. surveys and active *surveillance*) and non-structured (e.g. passive *surveillance*) sources should be combined and the sensitivity of each activity should be quantified in order to be able to quantify the sensitivity of the overall *surveillance* system.

The *surveillance* programme should include *surveillance* for high pathogenicity avian influenza viruses in birds other than *poultry,* including *wild* birds, and *monitoring* of low pathogenicity avian influenza viruses in *poultry*, in order to ensure that *biosecurity* and control measures are fit for purpose.

Documentation of freedom from *infection* with high pathogenicity avian influenza should provide details of the *poultry* population, the occurrence of suspected *cases* and how they were investigated and dealt with. This should include the results of *laboratory* testing and the *biosecurity* and control measures to which the animalsconcerned were subjected during the investigation.

2. Additional requirements for countries, zones or compartments that practise vaccination

*Vaccination* to prevent the transmission of high pathogenicity avian influenza virus may be part of a diseasecontrol programme. The level of *flock* immunity required to prevent transmission depends on the *flock* size, composition (e.g. species) and density of the susceptible *poultry* population. Based on the epidemiology of avian influenza in the country, *zone* or *compartment*, a decision may be reached to vaccinate only certain species or other *poultry subpopulations*.

In all vaccinated *flocks* tests should be performed to ensure the absence of virus circulation. The tests should be repeated at a frequency that is proportionate to the *risk* in the country, *zone* or *compartment*. The use of sentinel *poultry* may provide further confidence in the absence of virus circulation.

Member Countries seeking the demonstration of freedom from high pathogenicity avian influenza in vaccinated population should refer to the chapter on avian influenza (*infection* with avian influenza viruses) in the *Terrestrial Manual*.

Evidence to show the effectiveness of the *vaccination* programme should also be provided.

Annex 12A (contd)

3. Additional requirements for recovery of free status

In addition to the conditions described in the point above, a Member Country declaring that it has regained country, *zone* or *compartment* freedom after an *outbreak* of high pathogenicity avian influenza in *poultry* should show evidence of an active *surveillance* programme, depending on the epidemiological circumstances of the *outbreak*,to demonstrate the absence of the *infection*. This will require *surveillance* incorporating virus detection and antibody tests. The Member Country should report the results of an active *surveillance* programme in which the susceptible *poultry* population undergoes regular clinical examination and active *surveillance* planned and implemented according to the general conditions and methods described in these recommendations. The *surveillance* samples should be representative of *poultry* *populations* at risk. The use of sentinel birds may facilitate the interpretation of *surveillance* results.

*Populations* under this *surveillance* programme should include:

*a)* *establishments* in the proximity of the *outbreaks*;

*b)* *establishments* epidemiologically linked to the *outbreaks*;

*c)* *poultry* used to re-populate affected *establishments*;

*d)* any *establishments* where preventive depopulation has been carried out.

Article 10.4.22bis.

**Surveillance of wild bird populations**

Passive *surveillance*, i.e. sampling of birds found dead, is an appropriate method of *surveillance* in *wild* birds because *infection* with high pathogenicity avian influenza can be associated with mortality in some species. Mortality events, or clusters of birds found dead should be reported to the local *Veterinary Authorities* and investigated, including through the collection and submission of samples to a *laboratory* for appropriate tests.

Active *surveillance,* i.e. sampling of live *wild* birds, may be necessary for detection of some strains of high pathogenicity avian influenza viruses that produce *infection* without mortality in *wild* birds. Furthermore, it increases knowledge of the ecology and evolution of avian influenza viruses.

*Surveillance* in *wild* birds should be targeted towards times of year, species and locations in which *infection* is more likely.

*Surveillance* in *wild* birds should be enhanced by raising awareness, and by active searching and *monitoring* for dead or moribund *wild* birds when high pathogenicity avian influenza has been detected in the region. The movements of migratory water birds, in particular ducks, geese and swans, should be taken into account as a potential pathway for introduction of virus to uninfected areas.

Article 10.4.22ter.

**Monitoring of low pathogenicity avian influenza in poultry populations**

*Outbreaks* of low pathogenicity avian influenza viruses can be managed at the *establishment* level; however, spread to other *poultry* *establishments* increases the risk of virus mutation, particularly if it is not detected and managed. Therefore, a *monitoring* system should be in place.

*Monitoring* the presence and types of low pathogenicity avian influenza viruses can be achieved through a combination of clinical investigation when *infection* is suspected because of changes in production parameters, such as reductions in egg production or *feed* and water intake, and active serological and virological *surveillance*, which can be supported by the information obtained by the *surveillance* system for high pathogenicity avian influenza.

Annex 12A (contd)

Serological and virological *monitoring* should aim at detecting clusters of infected *flocks* to identify spread between *establishments*. Epidemiological follow-up (tracing forward and back) of serologically positive *flocks* should be carried out to determine whether there is clustering of infected *flocks* regardless of whether the seropositive birds are still present at the *establishment* or whether active virus *infection* has been detected. Hence, *monitoring* of low pathogenicity avian influenza will also enhance early detection of high pathogenicity avian influenza.

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_